Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Read more about Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update Read more about Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update Read more about Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update Read more about Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference Read more about Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements Read more about Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market Read more about Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market